Individual immunosuppressive protocol after liver transplantation in benign end-stage liver disease: a single-center experience of 645 cases
10.3760/cma.j.issn.0254-1785.2011.07.011
- VernacularTitle:终末期良性肝病患者肝移植后免疫抑制治疗单中心经验总结
- Author:
Yunjin ZANG
;
Fengdong WU
;
Zhongyang SHEN
- Publication Type:Journal Article
- Keywords:
Liver transplantation;
Immunosuppression
- From:
Chinese Journal of Organ Transplantation
2011;32(7):419-422
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the individual immunosuppressive protocol (IP) after liver transplantation (LT) in benign end-stage liver disease. Methods The clinical data of 645 patients with benign end-stage liver disease undergoing LT in our institute from April 2002 to Aug 2010 wen analyzed retrospectively. 146 cases from Apr. 2002 to Dec. 2004 were in stage one, and triple therapy containing tacrolimus (Tac), mycophenolate mofetil (MMF) and methylprednisolone (MP) was used;273 cases from Jan. 2005 to Dec 2007 were in stage two, and the less dose of immunosuppressant than stage one was used; 226 cases from Jan. 2008 to Aug. 2010 were in stage three, and they wen divided into conventional group and severe patient group according to their preoperative model for endstage liver disease (MELD) score and patient condition, the individual IP was used. Results The overall survival rate of patients with MELD score <25 was 88. 9 % in stage one, 94. 2 % in stage two, and 95. 4 % in stage three; The overall survival rate of patients with MELD score ≥25 was 67. 7 % in stage one, 73. 4 % in stage two, and 82. 0 % in stage three. The incidence of rejection ir cases with MELD score <25 had no significant difference (P>0. 05). The incidence of rejection in cases with MELD score ≥25 in stage two and stage three was higher slightly than in stage one (P<0. 05). Conclusion The IP after liver transplantation should be individualized according to recipient conditions, which can increase survival rate.
